Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study
Petrakis I, Nolen T, Vandergrift N, Hirsch S, Krystal J, De Vivo M, Sabados J, Pisani E, Newcomb J, Kosten T. Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study. American Journal On Addictions 2024 PMID: 39152094, DOI: 10.1111/ajad.13637.Peer-Reviewed Original ResearchPathophysiology of posttraumatic stress disorderAlcohol use disorderSubjective effects of alcoholEffects of alcoholUse disorderComorbid alcohol use disorderAlcohol cue reactivityPosttraumatic stress disorderCrossover laboratory studyCue reactivityAlcohol cravingNoradrenergic dysregulationStress disorderBlood pressureSubjective effectsEthanol administrationClinically significant adverse effectsPharmacotherapeutic approachesTest daysReceptor agonistsPotential treatmentDouble-blind fashionCravingDrinking alcoholDisordersThe Impact of High-Potency Synthetic Opioids on Pharmacotherapies for Opioid Use Disorder: A Scoping Review
Jegede O, De Aquino J, Hsaio C, Caldwell E, Funaro M, Petrakis I, Muvvala S. The Impact of High-Potency Synthetic Opioids on Pharmacotherapies for Opioid Use Disorder: A Scoping Review. Journal Of Addiction Medicine 2024, 18: 499-510. PMID: 39356620, PMCID: PMC11449257, DOI: 10.1097/adm.0000000000001356.Peer-Reviewed Original ResearchNonmedical opioid useOpioid use disorderOpioid useWithdrawal symptomsTreatment outcomesSymptoms prior to treatmentUse disorderRisk of precipitated withdrawalLow-dose buprenorphineSynthetic opioidsPotency synthetic opioidsConclusions Current evidencePrecipitated withdrawalRisk of overdoseDosing strategiesPharmacological interactionsClinical significanceDecreased riskWeb of ScienceOpioidInclusion criteriaCurrent evidenceClinical implicationsMOUDPainThe combination of donepezil and cognitive training for improving treatment outcomes for alcohol use disorder: Design of a randomized controlled trial
Yoon G, Sofuoglu M, Petrakis I, Pittman B, Bell M. The combination of donepezil and cognitive training for improving treatment outcomes for alcohol use disorder: Design of a randomized controlled trial. Contemporary Clinical Trials 2024, 145: 107657. PMID: 39111388, PMCID: PMC11423257, DOI: 10.1016/j.cct.2024.107657.Peer-Reviewed Original ResearchCognitive remediation therapyAlcohol use disorderAlcohol use disorder treatment outcomesNeurocognitive functionCombination of donepezilRemediation therapyUse disorderTreatment outcomesDevelopment of alcohol use disordersReduce heavy drinking daysHeavy drinking daysGlobal neurocognitive functioningImprove neurocognitive functionEnhanced neurocognitive functionImprove cognitive functionRandomized controlled trialsReduce alcohol consumptionNeurobiological evidenceDrinking daysNeurocognitive function scoresCognitive trainingVA Connecticut Healthcare SystemCognitive functionImprove treatment outcomesCognitive impairmentAlcohol Use Disorder and Chronic Pain: An Overlooked Epidemic
De Aquino J, Sloan M, Nunes J, Costa G, Katz J, de Oliveira D, Ra J, Tang V, Petrakis I. Alcohol Use Disorder and Chronic Pain: An Overlooked Epidemic. American Journal Of Psychiatry 2024, 181: 391-402. PMID: 38706339, PMCID: PMC11521207, DOI: 10.1176/appi.ajp.20230886.Peer-Reviewed Original ResearchConceptsAlcohol use disorderChronic painAUD studiesChronic pain disordersChronic pain outcomesRisk of relapseAlcohol withdrawal syndromeAssessment of painHigher levels of alcohol consumptionLevels of alcohol consumptionWithdrawal syndromePain disordersPain outcomesAcute toleranceNeurobiological changesClinical significanceUse disorderPainClinical relevanceSelf-reportAlcohol intoxicationAlcohol consumptionGeneral populationMedical conditionsNarrative reviewCognitive processing therapy (CPT) versus individual drug counseling (IDC) for PTSD for veterans with opioid use disorder maintained on buprenorphine
Petrakis I, Meshberg‐Cohen S, Nich C, Kelly M, Claudio T, Jane J, Pisani E, Ralevski E. Cognitive processing therapy (CPT) versus individual drug counseling (IDC) for PTSD for veterans with opioid use disorder maintained on buprenorphine. American Journal On Addictions 2024, 33: 525-533. PMID: 38624259, DOI: 10.1111/ajad.13557.Peer-Reviewed Original ResearchCognitive processing therapyIndividual drug counselingPosttraumatic stress disorderOpioid use disorderSubstance use disordersDrug counselingProcessing therapyPTSD symptomsUse disorderCognitive processing therapy groupEvidence-based trauma-focused psychotherapiesSelf-reported PTSD symptomsPosttraumatic stress disorder symptomsPosttraumatic stress disorder treatmentRemission of PTSD symptomsPosttraumatic Stress Disorder ChecklistComorbid opioid use disorderTrauma-focused psychotherapyTrauma-focused treatmentRates of comorbidityTreatment group differencesPCL-5Stress disorderGroup differencesRandomized clinical trialsProblematic Alcohol Use Trajectories in U.S. Military Veterans during a Public Health Crisis: Results from a 3-year, Nationally Representative, Longitudinal Study
Na P, Fischer I, Petrakis I, Pietrzak R. Problematic Alcohol Use Trajectories in U.S. Military Veterans during a Public Health Crisis: Results from a 3-year, Nationally Representative, Longitudinal Study. Psychiatric Quarterly 2024, 95: 157-171. PMID: 38319532, PMCID: PMC11521206, DOI: 10.1007/s11126-024-10067-w.Peer-Reviewed Original ResearchConceptsDrug use disordersProblematic alcohol useAlcohol use trajectoriesLow social supportAdverse childhood experiencesAlcohol useGreater household incomeSocial supportUS veteransLongitudinal studyNational Health and ResilienceLatent growth mixture modelingU.S. military veteransHousehold incomeGrowth mixture modelingNon-household membersCOVID-19 pandemicVeterans StudyUse disorderMilitary veteransChildhood experiencesPublic health crisisPsychosocial characteristicsPrevention effortsVeterans